Skip to main content

Table 4 Percentage of variation in Foxp3+Treg and lymphocyte count

From: Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

  Foxp3+Tregs (%) before and after TMZ All lymphocytes (%) before and after TMZ Foxp3+Tregs after TMZ and IL-2 All lymphocytes (%) after TMZ and IL-2 Foxp3+Tregs before and after TMZ Foxp3+Tregs after TMZ and IL-2 Basal Foxp3+Tregs (%) after IL-2 All basal lymphocytes (%) after IL-2
1st cycle 1st cycle 1st cycle 1st cycle 4th cycle 4th cycle 4th cycle 4th cycle
All patients 60 . 5 p  =  0 . 017 14 . 2 p  =  0 . 020 +75.4 +15 −5.5 +38.6 −20.3 −4.0
DCR −30.2 −11.9 −33.8 −22.2 −5.3 +53.2 −37.4 −16.4
PD 76 . 4 p  =  0.032 −17.1 +388.9 +32.9 −22 +38.6 −20.3 +7.8
  1. TMZ Temozolomide, IL-2, Interleukin-2, DCR Disease control patients, PD Progressive disease patients.